Passage BIO (PASG) Research & Development (2019 - 2026)
Passage BIO (PASG) posted quarterly Research & Development of $4.1 million for Q1 2026, down 47.1% year-over-year from $7.7 million in Q1 2025, and down 24.46% quarter-over-quarter from $5.4 million in Q4 2025.
Passage BIO (PASG) Research & Development (2019 - 2026) Analysis & Trends
Passage BIO's Research & Development history runs 8 years deep, the most recent figure standing at $4.1 million for Q1 2026.
- In Q1 2026, Research & Development fell 47.1% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $19.6 million (down 46.04% YoY), while the FY2025 annual figure was $23.3 million, down 42.07% from the prior year.
- Research & Development for Q1 2026 stood at $4.1 million, down from $5.4 million in the prior quarter.
- The five-year high for Research & Development was $26.8 million in Q2 2022, with the low at $4.1 million in Q1 2026.
- The 5-year median for Research & Development is $11.5 million (2024), against an average of $12.6 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development grew 4.98% in 2022, then plunged 50.24% in 2025.
- Passage BIO's Research & Development stood at $17.7 million in 2022, then sank by 31.13% to $12.2 million in 2023, then slipped by 21.4% to $9.6 million in 2024, then sank by 43.31% to $5.4 million in 2025, then retreated by 24.46% to $4.1 million in 2026.
- Business Quant data shows PASG's Research & Development at $4.1 million in Q1 2026, $5.4 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 4.09 Mn |
| Dec 31, 2025 | 5.42 Mn |
| Sep 30, 2025 | 4.31 Mn |
| Jun 30, 2025 | 5.81 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Dec 31, 2024 | 9.56 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 10.43 Mn |
| Mar 31, 2024 | 11.54 Mn |
| Dec 31, 2023 | 12.16 Mn |
| Sep 30, 2023 | 15.10 Mn |
| Jun 30, 2023 | 17.32 Mn |
| Mar 31, 2023 | 16.84 Mn |
| Dec 31, 2022 | 17.66 Mn |
| Sep 30, 2022 | 15.36 Mn |
| Jun 30, 2022 | 26.82 Mn |
| Mar 31, 2022 | 26.21 Mn |
| Dec 31, 2021 | 32.97 Mn |
| Sep 30, 2021 | 26.62 Mn |